Compare Ascendis Pharma A/S (ASND) vs W W Grainger Inc (GWW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs W W Grainger Inc — how do they compare? Ascendis Pharma A/S trades at $263 (market cap $17.74B), while W W Grainger Inc trades at $1,377.57 (market cap $64.95B). The key difference: W W Grainger Inc is far larger — about 3.7× Ascendis Pharma A/S's market cap, and W W Grainger Inc pays a 0.67% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | GWW | |
|---|---|---|
Market Cap | $17.74B | $64.95B |
Sector | Health | Technology |
52-Week High | $277.18 | $1.38K |
52-Week Low | $163.32 | $918.18 |
Enterprise Value | $18.11B | $67.04B |
Dividend Yield | — | 0.67% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
GWW trades at $1,375.76, up 0.8% recently, with a bullish technical signal from moving averages and strong support at $1,356. The company reported Q1 2026 EPS of $11.65, beating estimates, and raised full-year guidance, reflecting robust MRO demand. Revenue growth to $18.4B in 2026 and a high ROE of 48.1% underscore operational strength, though valuation multiples like P/E of 36.99 appear elevated relative to historical norms.
Outlook is positive driven by earnings momentum and dividend consistency, but risks include high valuation sensitivity and industrial sector cyclicality. Analyst consensus is mixed with a $1,260 price target, suggesting cautious optimism amid growth execution risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About W W Grainger Inc
Grainger is a leading broad-line distributor of maintenance, repair, and operating (MRO) products. It serves millions of customers worldwide through an integrated network of branches and digital platforms.
Read more on GWW →
